As an internationally recognized laboratory label brand, BRADY occupies an important position in the global cryogenic label market. However, issues such as high prices, long lead times, and limited customization of imported products have constrained domestic users' procurement. The domestic cryogenic label solution launched by BRD provides users with a reliable alternative.
I. Background of Domestic Substitution
In recent years, with the rapid development of the domestic biopharmaceutical industry and growing awareness of supply chain autonomy and controllability, more and more institutions have begun to focus on domestic substitution of laboratory consumables and labels. With years of technical accumulation and market experience, BRD has launched domestic cryogenic labels benchmarked against international brands.
II. Product Performance Comparison
Low-temperature resistance: BRD domestic labels use polyester face stock and low-temperature adhesive of the same grade as imported brands, performing stably within the range of -196 °C to room temperature.
Printing compatibility: The labels are compatible with BRADY brand and mainstream thermal-transfer printers, delivering clear and durable print results.
Specification variety: Multiple sizes, colors, and roll formats are available to meet the needs of different specimen containers and application scenarios.
Cost-effectiveness: Compared with imported products, domestic labels offer a clear price advantage, reducing procurement costs by 30%–50% for users.
III. Application Scenarios
This solution is suitable for institutions with high demand for cryogenic labels, including hospital clinical laboratories, biobanks, CDC centers, research institutes, and pharmaceutical companies.
IV. Application Cases
After trialing BRD domestic cryogenic labels, multiple domestic biobanks and medical institutions confirmed that their performance is comparable to imported products and gradually completed the substitution from imported to domestic products.
V. Service Commitment
BRD provides free sample testing, application technical support, and customization services to help users smoothly complete domestic substitution.
Related Compliance Standards
For the domestic cryogenic label solution, production quality control references ISO 13485:2016 Medical Devices — Quality Management Systems, product performance meets the specimen identification requirements of ISO 20387:2018, and adhesive reliability is verified with reference to GB/T 2792-2014.
Featured Products
For the label materials and application scenarios covered in this article, the following BRD products are available for selection reference (click to view specifications and request a quote):
- BBP12 BRADY laboratory research institution medical biological sample bank cryogenic LN₂ label printer (Request a Quote)
- MACH4S laboratory equipment LN₂ cryovial microscope slide biological sample bank cryogenic LN₂ label printer (Request a Quote)
- EOS2/3 biological sample bank label printer medical laboratory cryogenic LN₂ cryovial conical tube microcentrifuge tube (Request a Quote)
- BRADY i7500 laboratory research institution medical biological sample bank cryogenic label printer (Request a Quote)
FAQ
Q: What are the advantages of domestic cryogenic labels?
Shorter lead times, lower costs, support for small-batch customized orders, and fast local service response. In recent years, the performance of leading domestic products has been benchmarked against imported products.
Q: How do domestic labels ensure compatibility with Brady printing equipment?
High-quality domestic cryogenic labels undergo compatibility testing for mainstream printing equipment (including the Brady series). Users can request compatibility reports or sample proofing verification before procurement.
Q: How is the quality of domestic cryogenic labels verified?
Request third-party test reports from suppliers (low-temperature peel strength, freeze–thaw cycles, barcode grade), and conduct your own verification at the target temperature.
Considerations for Domestic Substitution of Cryogenic Labels
Domestic cryogenic labels have gradually gained the capability to replace imported products in performance, delivery, and cost, but substitution should be objectively evaluated from multiple dimensions beforehand.
| Dimension | Imported Solution | Domestic Solution |
|---|---|---|
| Face stock system | Full range of PET/PP/PI | Full coverage of mainstream face stocks |
| Adhesive | Mature low-Tg cryogenic adhesives | Benchmark-developed, stable performance |
| Lead time | Import-dependent, long lead times | Localized, short lead times |
| Cost | Relatively high | Generally more cost-effective |
Performance Benchmarking and Verification for Domestic Substitution
The core of substitution is not "changing brands" but "performance benchmarking." It is recommended to use the existing labels as the baseline and conduct parallel comparison tests on four items: temperature range, freeze–thaw cycle resistance, barcode readability, and peel strength, verified with reference to GB/T 2792-2014 and ISO/IEC 15416, and switch only after all items meet the standards. Overall specimen identification must meet the requirements of ISO 20387:2018 for biobanks.
Comprehensive Benefits of Domestic Substitution
For laboratories and biobanks, domestic cryogenic labels—while ensuring performance—can shorten supply cycles, reduce unit costs, and support more flexible small-batch customization and rapid response. Achieving a smooth transition through standardized benchmarking verification is a pragmatic choice that balances quality, cost, and supply security.
Supply Chain Advantages of Domestic Cryogenic Labels
The supply chain advantages of domestic cryogenic labels are mainly reflected in three aspects: first, short lead times—localized production and inventory can quickly respond to small-batch, multi-variety demand; second, flexible customization—rapid adjustment of sizes, materials, and printing solutions; third, more competitive overall costs, especially suitable for routine consumable procurement by large-scale biobanks. On the premise of meeting performance benchmarks, the domestic solution is a pragmatic choice that balances quality and supply.
Implementation Path for Domestic Substitution
Domestic substitution is recommended to proceed in four steps: first, review the specifications, performance, and usage scenarios of existing labels; second, select 2–3 domestic brands for sample and parameter benchmarking; third, conduct small-batch parallel testing (same batch and same environment as the existing labels); fourth, after all indicators meet the standards, switch in batches while maintaining a dual-track observation period. Gradual switching can effectively control substitution risks.
Quality Assurance System for Domestic Labels
Mature domestic label manufacturers generally have established quality control systems covering raw materials, production, and finished products, and provide factory inspection reports on temperature resistance, adhesion, and printing. During procurement, users can request third-party test reports and conduct incoming inspections with reference to GB/T 2792-2014 and ISO/IEC 15416. Using measured data as the acceptance basis ensures batch consistency of domestic labels.
Value and Significance of Domestic Substitution
Promoting domestic cryogenic labels is not only a cost consideration but also a safeguard for supply chain security. Against the backdrop of rapid development in the biopharmaceutical industry, stable local supply can reduce supply disruption risks and shorten response times. Achieving domestic substitution through scientific benchmarking and rigorous verification can create more reliable and economical identification solutions for laboratories and biobanks without sacrificing quality.
Risk Control for Domestic Substitution
Key risk control points for domestic substitution of cryogenic labels: maintain parallel use of the original solution for a period, prioritize verification in critical scenarios (LN₂), and establish incoming inspection and batch sample retention. Gradual switching plus data-based acceptance can minimize substitution risks and achieve a balance between quality and cost.